Corporate Profile
Amgen, a global biotechnology leader, is dedicated to serving patients by developing innovative medicines for some of the world’s most serious diseases. For over 40 years, Amgen has been at the forefront of the biotech industry, using cutting-edge science to significantly improve lives and reduce the burden of illness.
As a leading independent biotech company, Amgen focuses on high unmet medical needs, with a robust pipeline covering all stages of drug development. The company targets various therapeutic areas, including cancer, cardiovascular disease, inflammation, bone health, and nephrology.
With a presence in around 100 countries, Amgen is committed to reaching patients worldwide with its life-changing treatments. The company’s dedicated team works tirelessly to transform bold breakthroughs into powerful medicines that make a meaningful difference for millions.
Founded in 1980 in Thousand Oaks, California, Amgen operates as one integrated human therapeutics business, unlocking the potential of biology for patients suffering from serious illnesses.
Amgen: A five minute history
Top-selling products
- Enbrel (etanercept) – Used to treat autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis.
- Prolia (denosumab) – Used to treat osteoporosis in postmenopausal women and men at high risk for fracture.
- Neulasta (pegfilgrastim) – Used to reduce the chance of infection in patients undergoing chemotherapy.
- Xgeva (denosumab) – Used to prevent skeletal-related events in patients with bone metastases from solid tumors.
- Otezla (apremilast) – Used to treat psoriatic arthritis and moderate to severe plaque psoriasis.
- Aranesp (darbepoetin alfa) – Used to treat anemia associated with chronic kidney disease or chemotherapy.
- Kyprolis (carfilzomib) – Used to treat multiple myeloma, a type of blood cancer.
- Repatha (evolocumab) – Used to lower LDL cholesterol in patients with hereditary high cholesterol or cardiovascular disease.
- Nplate (romiplostim) – Used to treat low blood platelet counts in adults with chronic immune thrombocytopenia.
- Vectibix (panitumumab) – Used to treat metastatic colorectal cancer in patients with wild-type KRAS tumors.
Key clinical candidates -- as of June 2024
- AMG 133 – For obesity and weight management
- AMG 998 – For asthma and other respiratory conditions
- AMG 714 (rozibafusap) – For celiac disease
- Tarlatamab (AMG 757) – For small cell lung cancer
- AMG 176 – For acute myeloid leukemia and other hematologic malignancies
- AMG 199 – For metastatic castration-resistant prostate cancer
- AMG 509 – For prostate cancer
- AMG 340 – For metastatic castration-resistant prostate cancer
- AMG 330 – For acute myeloid leukemia
- AMG 910 – For gastric and gastroesophageal junction cancers
- Olpasiran (AMG 890) – For cardiovascular disease risk reduction
- Rocatinlimab (AMG 451/KHK4083) – For atopic dermatitis
- AMG 119 – For small cell lung cancer
Investing profile
Amgen (NASDAQ: AMGN)
Industry: Biotechnology
Industry 10-Year Outlook: Positive
Biotechnology is poised for substantial growth from 2024 to 2034, driven by an aging global population, increased healthcare access, and continuous innovation in the field.
Stock Overview
Amgen stock has demonstrated remarkable long-term performance since its IPO (Initial Public Offering) on June 17, 1983.
- Total percentage return on capital since IPO: 125,300% (including dividends and assuming dividend reinvestment)
- This extraordinary return highlights Amgen’s success in translating scientific breakthroughs into shareholder value over decades.
__________________________________________________
Dividend Profile
- Average five-year dividend yield: 3%
- Five-year dividend growth rate: 9.8%
- Five-year average payout ratio: 55.9%
Amgen has shown a strong commitment to returning value to shareholders through a growing dividend program.
The healthy dividend growth rate, coupled with a reasonable historical payout ratio, suggests sustainability in dividend payments.
__________________________________________________
Key Growth Metrics
- Five-year free cash flow growth rate: -4.35%
- Five-year average revenue growth rate: 4.13%
- Five-year average diluted earnings per share growth rate: -0.61%
Disclosure:
The information presented here is based on historical data and publicly available sources. It is intended for informational purposes only and should not be considered as financial advice or a recommendation to buy or sell any security. Past performance does not guarantee future results. All data is derived from Yahoo! Finance.
Latest company news
